ArticleMedicine2025
Machine learning reveals ferroptosis and therapeutic targets in rheumatoid arthritis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global research trends in programmed cell death in rheumatoid arthritis from 2001 to 2025: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A complex, multisystem, chronic autoimmune disease, rheumatoid arthritis (RA) severely impairs a patient's quality of life and finances. Though the precise chemical process is unclear, ferroptosis, a recently studied method of cell death, plays a significant role in RA. Furthermore, despite the fact that Chinese medicine, particularly the usage of Taohong Siwu Decoction (THSWD), has substantial benefits in treating RA, there are numerous shortcomings in the way RA is currently treated. In order to determine the primary acting components of THSWD and the primary acting targets that influence RA Ferroptosis based on network pharmacology, we will use machine learning to identify the major targets and molecular processes of Ferroptosis in RA. The main components and underlying molecular mechanisms of THSWD treatment for RA were elucidated by molecular docking techniques and in vitro experiments. Ferroptosis marker genes were found to be PTGS2, SLC40A1, TF, TFRC, FTH1, GPX4, HSPB1, and NFE2L2 in RA in microarray data analysis. Furthermore, we used ATF3, EGR1, and KDM6B as the ferroptosis activator genes. Ferroptosis inhibitor genes included ZFP36, NR4A1, CDKN1A, ABRD4, and RRM2. The disease process of RA may be linked to intracellular iron-ion homeostasis, iron-ion transport, and oxidative stress response, according to bioinformatic study. KEGG bioprocesses indicate that ferroptosis, the HIF-1 signaling pathway, and the p53 signaling pathway are closely linked to the development of RA. Lastly, using network pharmacology and vitro experiment, we discovered that kaempferol, a crucial part of THSWD, controlled ferroptosis to enhance RA through TFRC, ZFP36, PTGS, CDKN1A, and ATF3. The multi-component, multi-target, and multi-pathway features of THSWD for RA were demonstrated by this research investigation, which further elucidated the mechanism of THSWD for RA treatment with fresh perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.